ARTICLE | Clinical News

Humira adalimumab: Phase III started

March 31, 2014 7:00 AM UTC

AbbVie began a double-blind, placebo-controlled, international Phase III trial to evaluate subcutaneous Humira given every other week for 26 weeks in about 200 adults with moderate to severe chronic plaque psoriasis and >=1 fingernail with nail psoriasis. Humira is approved in the U.S. and EU to treat adults with moderately to severely active Crohn's disease (CD), moderate to severe rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis and ulcerative colitis (UC) and to treat polyarticular juvenile idiopathic arthritis in patients >=4 years old. ...